Topic

Mike Hollan is an Editor for Pharm Exec. He can be reached at 

Articles

Tracking the pandemic’s influence on brand awareness and prescribing efforts in light of decline in physician visits and fewer diagnoses—and what these dynamics, still unsettled post-pandemic, might mean for future launches.

Assessing HCP-Visit Fallout: COVID’s Ultimate Impact on New Drug Entrants 

Dr. Kyle Flanigan, Ph.D., discusses the benefits of an oral COVID-19 vaccine.

Q&A with Dr. Kyle Flanigan, Ph.D., Co-Founder and CEO of USSF

Round discusses how he adjusted his leadership style and approach to patient care in the most effective way during the pandemic.

Q&A With Chris Round, president, EMD Serono

Seth Lederman, MD, is a physician-scientist and CEO of New Jersey-based Tonix Pharmaceuticals, a company developing technologies to prevent COVID-19 and treat long COVID. His research led to the discovery of the CD40 ligand and its role in T-cell helper function.

Industry must continue research and development to combat the pandemic.

Why Are We Surrendering to COVID?

Alisa Hummings is senior director, IQVIA Medical Information and CEVA

Simon Johns is director, IQVIA Medical Information and Marketed Product Safety

COVID-19 pandemic has accelerated raised expectations for medical information professionals.

The Agile Future of Medical Information: Meeting 21st-Century Demands for Healthcare

Steve Scalia is president of Tanner Pharm Group

Bob Mulroy is director and chief executive officer of Partner Therapeutics

John L. McManus is chief business officer of Partner Therapeutics

Recent explosion at Zaporizhzhia nuclear power plant in Ukraine shows how pharma industry can pull together and take action in the face of adversity.

Partnering to Respond to a Possible Nuclear Threat

Sadik Kassim is chief technology officer, Genomic Medicines for the Life Sciences companies at Danaher Corporation, which include Aldevron, Integrated DNA Technologies (IDT), SCIEX, Beckman Coulter Life Sciences, and Precision NanoSystems

Improvements in R&D, manufacturing, and data sharing will extend platform’s reach.

Three Key Steps to Unlocking mRNA’s Potential Beyond COVID-19

Managing Vice President at the Philadelphia Office of Pariveda

Industry has shown it can overcome challenges en route to creating new therapies.

What the COVID-19 Vaccine Process Showed Us, and How It Can Impact the Future of Drug Development

Jill Wechsler is Pharm Exec's Washington Corespondent

On December 22, 2021, FDA authorized emergency use of Pfizer’s oral antiviral drug Paxlovid on December 22, 2021, skipping the advisory committee review to make the drug available as quickly as possible. The following day, FDA provided similar authorization for Merck’s Molnupiravir.

Here Come the COVID Treatment Options

Lisa Henderson is the group editorial director of 

 and can be reached at lhenderson@mjhlifesciences.com.

While pharma has reached new heights in vaccine development, many questions remain around the lasting effects of COVID and how future therapies can curb them.